2025
Hypoxia-induced Wnt5a-secreting fibroblasts promote colon cancer progression
Harada A, Yasumizu Y, Harada T, Fumoto K, Sato A, Maehara N, Sada R, Matsumoto S, Nishina T, Takeda K, Morii E, Kayama H, Kikuchi A. Hypoxia-induced Wnt5a-secreting fibroblasts promote colon cancer progression. Nature Communications 2025, 16: 3653. PMID: 40246836, PMCID: PMC12006413, DOI: 10.1038/s41467-025-58748-9.Peer-Reviewed Original ResearchConceptsColon cancer progressionSingle-cell RNA-seq dataCancer progressionEndothelial cellsRNA-seq dataColon cancer aggressivenessSuppression of angiogenesisColon cancer growthColon cancer formationCancer aggressivenessInflammatory fibroblastsVEGF receptor1Cancer growthPromote tumorigenesisCancer formationWnt5aMeta-analysisWnt ligandsLuminal sideFibroblast subtypesColonHypoxic environmentFibroblastsCells
2023
Tissue-specific biological aging predicts progression in prostate cancer and acute myeloid leukemia
Ramakrishnan A, Datta I, Panja S, Patel H, Liu Y, Craige M, Chu C, Jean-Marie G, Oladoja A, Kim I, Mitrofanova A. Tissue-specific biological aging predicts progression in prostate cancer and acute myeloid leukemia. Frontiers In Oncology 2023, 13: 1222168. PMID: 37746266, PMCID: PMC10512286, DOI: 10.3389/fonc.2023.1222168.Peer-Reviewed Original ResearchAcute myeloid leukemiaProstate cancerYears of ageAML progressionCancer progressionMyeloid leukemiaStratified survival analysisBiological agingHigh Gleason scoreCox proportional hazardsMarker of progressionProstate cancer progressionPersonalized therapeutic managementMultiple cancer typesAML incidenceOverall survivalPrognostic factorsGleason scoreTherapeutic managementPatient cohortRisk scorePatientsCancer aggressivenessChronological agingProportional hazards
2018
Prostate cancer aggressiveness and age: Impact of p53, BCL-2 and microvessel density
Calvocoressi L, Uchio E, Ko J, Radhakrishnan K, Aslan M, Concato J. Prostate cancer aggressiveness and age: Impact of p53, BCL-2 and microvessel density. Journal Of Investigative Medicine 2018, 66: 1142-1146. PMID: 30297390, DOI: 10.1136/jim-2018-000804.Peer-Reviewed Original ResearchConceptsGleason scoreMicrovessel densityProstate cancerBcl-2Prostate-specific antigen levelProstate cancer deathAdvanced prostate cancerAggressive prostate cancerB-cell lymphoma 2Prostate cancer aggressivenessPositive Bcl-2Impact of p53Cell lymphoma 2Anatomic stageMen 70Adjusted ORsAntigen levelsCategories of ageCancer deathElderly menDisease progressionImmunohistochemical stainingStudy populationCancer aggressivenessProstate tumors
2017
Tumor reactive stroma in cholangiocarcinoma: The fuel behind cancer aggressiveness
Brivio S, Cadamuro M, Strazzabosco M, Fabris L. Tumor reactive stroma in cholangiocarcinoma: The fuel behind cancer aggressiveness. World Journal Of Hepatology 2017, 9: 455-468. PMID: 28396716, PMCID: PMC5368623, DOI: 10.4254/wjh.v9.i9.455.Peer-Reviewed Original ResearchTumor reactive stromaReactive stromaCCA progressionStromal cellsAggressive epithelial malignancyReactive stromal cellsProgression of cholangiocarcinomaEarly lymphDismal prognosisBiliary carcinogenesisCancer cell behaviorConventional chemotherapyBreast carcinomaDesmoplastic microenvironmentEpithelial malignanciesCancer aggressivenessCell aggressivenessNeoplastic cellsCholangiocarcinomaMetastatic disseminationCombinatorial therapySoluble factorsCancer typesParacrine communicationExtracellular matrix
2016
The Role of p120‐catenin and PIK3CA in Migration in Head and Neck Squamous Cell Carcinoma
Kidacki M, Lehman H, Welsh P, Warrick J, Stairs D. The Role of p120‐catenin and PIK3CA in Migration in Head and Neck Squamous Cell Carcinoma. The FASEB Journal 2016, 30 DOI: 10.1096/fasebj.30.1_supplement.439.8.Peer-Reviewed Original ResearchNormal oral keratinocytesNeck squamous cell carcinomaSquamous cell carcinomaPIK3CA mutationsCell carcinomaInvasive capabilityCell linesBoyden chamber migration assaysPhospho-STAT3Time of diagnosisCell migrationE545KEpithelial cancer modelsMalignant cell populationMigration/invasionDistant metastasisSame patientCancer aggressivenessOral keratinocytesCancer modelPIK3CA mutantsTumorigenic effectsHNSCCPatientsMetastasis
2014
Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error
Shipitsin M, Small C, Choudhury S, Giladi E, Friedlander S, Nardone J, Hussain S, Hurley AD, Ernst C, Huang YE, Chang H, Nifong TP, Rimm DL, Dunyak J, Loda M, Berman DM, Blume-Jensen P. Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error. British Journal Of Cancer 2014, 111: 1201-1212. PMID: 25032733, PMCID: PMC4453845, DOI: 10.1038/bjc.2014.396.Peer-Reviewed Original ResearchMeSH KeywordsActininAgedAlkyl and Aryl TransferasesArea Under CurveBiomarkers, TumorBiopsy, Fine-NeedleCullin ProteinsDNA-Binding ProteinsFollow-Up StudiesHSP70 Heat-Shock ProteinsHumansImage Processing, Computer-AssistedMaleMembrane ProteinsMiddle AgedMitochondrial ProteinsNeoplasm GradingNeoplasm StagingPhosphorylationProstateProstatic NeoplasmsProteomicsRibosomal Protein S6RNA-Binding Protein FUSROC CurveSelection BiasSmad2 ProteinSmad4 ProteinTissue Array AnalysisVoltage-Dependent Anion Channel 1Y-Box-Binding Protein 1ConceptsProstate cancer aggressivenessCancer aggressivenessLarge patient cohortLow Gleason gradePatient cohortTumor microarrayLethal outcomeProstatectomy samplesGleason gradeSignificant overtreatmentBiopsy interpretationProstatectomy tissuePatient samplesBiopsy testsProteomic biomarkersCancer biomarker discoveryExpert pathologistsMarker signaturesTumor heterogeneityBiomarkersAggressivenessProtein biomarkersBiomarker discoveryQuantitative proteomics approach
2011
The Impact of Common Genetic Variations in Genes of the Sex Hormone Metabolic Pathways on Steroid Hormone Levels and Prostate Cancer Aggressiveness
Sun T, Oh W, Jacobus S, Regan M, Pomerantz M, Freedman M, Lee G, Kantoff P. The Impact of Common Genetic Variations in Genes of the Sex Hormone Metabolic Pathways on Steroid Hormone Levels and Prostate Cancer Aggressiveness. Cancer Prevention Research 2011, 4: 2044-2050. PMID: 21900597, PMCID: PMC3773969, DOI: 10.1158/1940-6207.capr-11-0283.Peer-Reviewed Original ResearchConceptsProstate cancer aggressivenessPlasma hormone levelsCancer aggressivenessHormone levelsSingle-nucleotide polymorphismsSteroid hormone levelsAssociated with plasma levelsSex hormone-binding globulinD'Amico risk classificationLocalized prostate cancerPlasma levels of steroid hormonesSex hormone metabolic pathwayGenetic variants of genesHormone-binding globulinEstrogen metabolism pathwayInherited variationHormone metabolic pathwaysBorderline significant associationLevels of steroid hormonesAssociation of genotypesVariants of genesPlasma testosterone levelsMetabolic pathwaysTumor gradeProstate cancerAssociation of Prostate Cancer Risk Loci with Disease Aggressiveness and Prostate Cancer–Specific Mortality
Pomerantz M, Werner L, Xie W, Regan M, Lee G, Sun T, Evan C, Petrozziello G, Nakabayashi M, Oh W, Kantoff P, Freedman M. Association of Prostate Cancer Risk Loci with Disease Aggressiveness and Prostate Cancer–Specific Mortality. Cancer Prevention Research 2011, 4: 719-728. PMID: 21367958, PMCID: PMC3811002, DOI: 10.1158/1940-6207.capr-10-0292.Peer-Reviewed Original ResearchConceptsProstate cancer-specific mortalityCancer-specific mortalityProstate-specific antigenProstate cancer risk variantsCancer risk variantsDisease aggressivenessSingle nucleotide polymorphismsGleason scoreProstate cancerAssociated with prostate cancer-specific survivalRisk variantsProstate cancer-specific deathAssociated with prostate cancer aggressivenessProstate cancer-specific survivalDiagnosis of prostate cancerCancer-specific survivalCancer-specific deathProstate cancer aggressivenessMen of European ancestryProstate cancer survivalAssociated with riskD'Amico criteriaClinical parametersClinical outcomesCancer aggressivenessInherited Variants in the Chemokine CCL2 Gene and Prostate Cancer Aggressiveness in a Caucasian Cohort
Sun T, Mary L, Oh W, Freedman M, Pomerantz M, Pienta K, Kantoff P. Inherited Variants in the Chemokine CCL2 Gene and Prostate Cancer Aggressiveness in a Caucasian Cohort. Clinical Cancer Research 2011, 17: 1546-1552. PMID: 21135144, PMCID: PMC3060307, DOI: 10.1158/1078-0432.ccr-10-2015.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAllelesChemokine CCL2Cohort StudiesDisease ProgressionGenetic Predisposition to DiseaseGenetic VariationGenotypeHaplotypesHumansLinkage DisequilibriumMaleMiddle AgedNeoplasm InvasivenessNeoplasm MetastasisPolymorphism, Single NucleotideProstatectomyProstatic NeoplasmsRiskConceptsC-C chemokine ligand 2Prostate cancer aggressivenessSingle nucleotide polymorphismsCancer aggressivenessMarkers of disease aggressivenessAssociated with advanced pathological stageBiopsy Gleason scoreGood-risk featuresProstate cancer developmentProstate cancer progressionAdvanced pathological stageChemokine ligand 2Associated with markersProstate cancer tumorigenesisGleason scoreRadical prostatectomyClinicopathological variablesPathological stageDisease aggressivenessPatient cohortG alleleGermline variantsCaucasian cohortProstateRisk features
2010
Single-Nucleotide Polymorphisms in p53 Pathway and Aggressiveness of Prostate Cancer in a Caucasian Population
Sun T, Lee G, Oh W, Pomerantz M, Yang M, Xie W, Freedman M, Kantoff P. Single-Nucleotide Polymorphisms in p53 Pathway and Aggressiveness of Prostate Cancer in a Caucasian Population. Clinical Cancer Research 2010, 16: 5244-5251. PMID: 20855462, PMCID: PMC2970725, DOI: 10.1158/1078-0432.ccr-10-1261.Peer-Reviewed Original ResearchMeSH KeywordsAgedBiomarkers, TumorCarcinomaCell Cycle ProteinsCohort StudiesDisease ProgressionGenetic Predisposition to DiseaseGenetics, PopulationHumansMaleMiddle AgedNeoplasm InvasivenessNuclear ProteinsPolymorphism, Single NucleotideProstatic NeoplasmsProto-Oncogene ProteinsProto-Oncogene Proteins c-mdm2Signal TransductionTumor Suppressor Protein p53Ubiquitin ThiolesteraseUbiquitin-Specific Peptidase 7White PeopleConceptsProstate cancer aggressivenessProstate cancer developmentSingle-nucleotide polymorphismsGleason scoreRadical prostatectomyProstate cancerCancer aggressivenessAssociated with high Gleason scoreAggressiveness of prostate cancerCancer developmentEarly onset prostate cancerSNP309T alleleP53 pathwayAssociation of single-nucleotide polymorphismsHigh Gleason scoreP53 Arg72Pro polymorphismProstate cancer cohortTime of diagnosisP53 pathway genesFunctional single-nucleotide polymorphismsStatistically significant associationHigher D'AmicoArg72Pro polymorphismClinicopathological variablesPathological variablesInherited Variations in AR, ESR1, and ESR2 Genes Are Not Associated With Prostate Cancer Aggressiveness or With Efficacy of Androgen Deprivation Therapy
Sun T, Lee G, Werner L, Pomerantz M, Oh W, Kantoff P, Freedman M. Inherited Variations in AR, ESR1, and ESR2 Genes Are Not Associated With Prostate Cancer Aggressiveness or With Efficacy of Androgen Deprivation Therapy. Cancer Epidemiology Biomarkers & Prevention 2010, 19: 1871-1878. PMID: 20615892, PMCID: PMC3755451, DOI: 10.1158/1055-9965.epi-10-0216.Peer-Reviewed Original ResearchConceptsAndrogen deprivation therapyResponse to ADTAssociated with prostate cancer aggressivenessProstate cancer aggressivenessDeprivation therapyESR2 geneCancer aggressivenessEfficacy of androgen deprivation therapyResponse to androgen deprivation therapySex steroid hormone receptorsAssociated with disease aggressivenessD'Amico risk classificationNormal prostate growthAggressive prostate cancerProstate cancer casesProstate cancer developmentTagging single nucleotide polymorphismsHospital-based cohortInherited variationSteroid hormone receptorsClinically relevant traitsProstate growthProstate cancerPathological stageDisease aggressiveness
2000
Comparison of the percent free prostate-specific antigen levels in the serum of healthy men and in men with recurrent prostate cancer after radical prostatectomy
Scorilas A, Yu H, Soosaipillai A, Gregorakis A, Diamandis E. Comparison of the percent free prostate-specific antigen levels in the serum of healthy men and in men with recurrent prostate cancer after radical prostatectomy. Clinica Chimica Acta 2000, 292: 127-138. PMID: 10686282, DOI: 10.1016/s0009-8981(99)00211-9.Peer-Reviewed Original ResearchConceptsPercent free PSAProstate cancer patientsFree PSAProstate cancerCancer patientsRadical prostatectomyPercent free prostate-specific antigen levelsCancer aggressivenessFree prostate specific antigen levelsProstate-specific antigen levelProstate cancer screening programsAge-matched menCancer screening programsRecurrent prostate cancerBenign prostatic hyperplasiaProstate cancer aggressivenessAntigen levelsTotal PSAGleason scoreHealthy menProstatic hyperplasiaProstatic diseaseScreening programPatientsPathological indicators
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply